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‘‘NO WASH’’ ALBUMIN-DEXTRAN DILUTION FOR DOUBLE-UNIT CORD
BLOOD TRANSPLANTATION (DCBT) IS SAFE WITH APPROPRIATE MAN-
AGEMENT AND RESULTS IN HIGH RATES OF SUSTAINED DONOR EN-
GRAFTMENT
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The wash of CB grafts involves additional product manipulation,
risks cell loss, & delays time to infusion.We have previously reported
that albumin-dextran dilution without centrifugation is feasible &
safe in recipients of red blood cell (RBC) depleted DCBT . 20
kg. Concern remains, however, about the risk of severe infusion re-
actions. We now report our experience in 108 ‘‘no wash’’ DCBT re-
cipients using RBC depleted units for the treatment of high-risk
hematologic malignancies between 2/2006-8/2011. A ‘‘no wash’’
DCBT was planned for one additional patient who developed an
anaphylaxis-type reaction 10 mls into the first unit (grade 3 severity
CTCAE v4.0), infusion was aborted, & the graft was washed. This
patient had similar reactions to blood products. The 108 patients
transplanted with a diluted graft [median 41 years (range 6-69) &
69 kg (range 24-111)] received myeloablative (n 5 80) or non-mye-
loablative (n5 28) conditioning, calcineurin-inhibitor/mycopheno-
late mofetil prophylaxis, & 4-6/6 HLA-matched grafts. Units were
diluted a median of 8 fold (range 6-12) using 5:1 10% dextran 40-
25% human serum albumin to a median final volume of 200 ml/
unit (range 200-600). The median infused TNC x 107/kg was 2.7
(larger unit) & 2.0 (smaller unit) with a median post-thaw recovery
of 86%. Units were infused consecutively [median 45 minutes/unit
(range 15-150)] after pre-medications (acetaminophen, diphenhy-
dramine, lorazepam). Infusion reactions & engraftment of the 108
patients transplanted with a diluted graft are shown (Table). While
only 16 patients (15%) had no reactions, reactions in remaining pa-
tients were mild-moderate (10 grade 1, 36 grade 2, 46 grade 3 by
CTCAE v4.0) & were easily treated. There were no grade 4-5 reac-
tions. The most common reaction was grade 2-3 hypertension in 81
(75%) patients requiring treatment in 55 (51%) with hydralazine
&/or furosemide. This was followed by nausea &/or vomiting (n
5 16, 15%). The cumulative incidence of sustained donor engraft-
ment was high: 94% for neutrophils & 85% for platelets. DCBT
with albumin-dextran dilution of RBC depleted grafts is safe& effec-
tive with high rates of engraftment in patients . 20 kg. Our results
are likely dependent on adequate dilution, slow infusion, & prompt
infusion reaction management. Mild-moderate reactions are com-
mon but are easily treated. This approach is not recommended for
patients with prior severe reactions to blood products, or for trans-
plantation of RBC-replete units.
Table. Infusion Reactions and Engraftment After ‘‘No Wash’’
DCBT (n 5 108)
Infusion Reactions by CTCAE v4No reaction n 5 16, 15%Maximum severity grade 1 n 5 10, 9%Maximum severity grade 2 n 5 36, 33%Hypertension alone 29Hypertension+other (grd 1 bradycardia or nausea/
vomiting)6Wheezing/chest tightness 1Maximum severity grade 3 n 5 46, 43%Hypertension alone 34Hypertension+other (grd 2 chills or tachycardia; grd 1
nausea/vomiting, chest pain, hypoxia, bradycardia or
fever)12Maximum severity grade 4-5 n 5 0, 0%Cumulative Incidence of Sustained Donor Engraftment
Neutrophil engraftment by day +45
All patients: 94% (95% CI: 90-99)
Myeloablative: 94% (95% CI: 88-100); median 25 days (range 13-43)
Non-myeloablative: 96% (95% CI: 88-100); median 10 days (range 7-36)
(Continued )Table. (Continued)
Infusion Reactions by CTCAE v4
Platelet engraftment to 20,000 by day +180
All patients: 85% (95% CI: 78-92)
Myeloablative: 84% (95% CI: 75-92); median 48 days (range 30-162)
Non-myeloablative: 89% (95% CI: 77-100); median 34 days (range 9-59)24
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We previously reported the efficacy/safety outcomes of the
CLASSIC I study in older patients (pts) with R/R AML (Kantarjian,
EHA 2011). In this report, we evaluate the outcomes of HSCT after
Clo+Ara-C or Ara-C alone in CLASSIC I.
CLASSIC I was a randomized, double-blind trial that compared
Clo+Ara-C toAra-C inpts$55 yearswithR/RAML.Ptswere random-
ized to either Clo 40 mg/m2 or placebo followed by Ara-C 1 g/m2 each
for 5 consecutive days. While the primary endpoint of OS did not
differ between arms, there were statistically significant improve-
ments in the secondary endpoints (ORR, CR & EFS) in the
Clo+Ara-C arm. In this post-hoc analysis, patient characteristics
and safety were analyzed for pts who underwent HSCT. Since the
median time to HSCT was 3.8 months from the initiation of the
study drug, a 4-month landmark analysis was conducted to evaluate
OS following HSCT.
Among 320 pts with centrally confirmed AML (median age,
67yrs), 66 (21%; median age 63.5 yrs) underwent HSCT
[Clo+Ara-C: n 5 34; Ara-C: n 5 32]. Of these, 47 pts (71%) went
to HSCT in CR; 36 in CR from study drug [Clo+Ara-C: n 5 22
vs Ara-C: n 5 14] and 11 in CR from alternative therapy. 64 pts re-
ceived an allogeneic transplant [sibling donor: n 5 46 (70%), unre-
lated donor: n 5 18 (27%)] and 2 (3%) were autologous
transplants. Preparative regimens included myeloablative in 22 pts
(33%) and reduced intensity conditioning/non-myeloablative in 43
pts (65%).
Multiple analyses were consistent with a survival benefit ofHSCT:
a naive estimate comparing OS in pts with and without HSCT; a 4-
month landmark analysis comparing OS in pts with and without
HSCT; and landmark analyses assessing the impact of HSCT on
OS for patients who achieved CR. Although there was evidence
that HSCT was associated with longer survival, there was little evi-
dence of a differential effect across the treatment arms (interaction p
5 0.32 [not shown]). Post HSCT safety findings were similar across
treatment arms and raised no new concerns.
S212 Oral PresentationsApproximately 20% of pts (median age 63.5 yrs) with R/R AML
proceeded to HSCT in the CLASSIC I. More pts in the Clo+Ara-
C arm underwent HSCT in CR from study drug. Pts that proceeded
to transplant had a longer OS compared to those who did not. Over-
all, this post-hoc analysis of the CLASSIC I study demonstrated that
subsequent HSCT in elderly pts with R/R AML was feasible and as-
sociatedwith longer survival; though therewas little evidence of a dif-
ferential effect across treatment arms.
Table. Landmark Analysis and Safety Data
Impact of HSCTon Overall
Survival;
HR (95% CI)Overall
(N 5 320)Clo + Ara-C
(N 5 162)Ara-C alone
(N 5 158)Naive estimate 0.30 (0.22, 0.42) – –Landmark analysis
on FAS patients
at 4 months0.59 (0.37, 0.92) – –Landmark analysis
on CR patients
at 4 months– 0.81 (0.40, 1.63) 0.61 (0.23, 1.60)Landmark analysis on CR
patients at 8 months– 0.50 (0.24, 1.01) 0.40 (0.16, 0.99)HSCT-Related Overall Clo + Ara-C Ara-C aloneSafety; n (%) (N 5 66 HSCT) (N 5 34 HSCT) (N 5 32 HSCT)100-day post-HSCT mortality 9 (13.6%) 4 (11.8%) 5 (15.6%)Acute GVHD (All grades) 11 (16.7%) 5 (14.7%) 6 (18.8%)Acute GVHD (Grade $3) 3 (4.5%) 1 (2.9%) 2 (6.3%)Chronic GVHD 1 (1.5%) 1 (2.9%) 0 (0.0%)VOD Complications 1 (1.5%) 0 (0.0%) 1 (3.1%)HSCT, hematopoietic stem cell transplantation; Clo, clofarabine; Ara-C,
cytarabine; FAS, full analysis set; CR, complete remission; GVHD, graft-
vs-host disease; VOD, veno-occlusive disease.25
FLUDARABINE AND CYCLOPHOSPHAMIDE (Flu-Cy) BASED CONDITION-
ING REGIMENS ARE ASSOCIATED WITH EXCELLENT OUTCOMES ESPE-
CIALLY IN LOW RISK PATIENTS WITH SEVERE APLASTIC ANEMIA (SAA)
George, B., Mathews, V., Ahmed, R., Abraham, A., Srivastava, A. Chris-
tian Medical College, Vellore, Tamilnadu, India
One hundred and five patients (68 men and 37 women) with a me-
dian age of 20 years (range: 2 – 53) with SAA underwent relatedHLA
identical stem cell transplantation (HSCT) using a conditioning reg-
imen of Fludarabine (180 mg/m2 over 6 days), Cyclophosphamide
(120 mg/kg over 2 days) 6 Anti- thymocyte globulin (40mg/kg
over 4 days) between 2004 and 2011. Cyclosporine with mini meth-
otrexate was used for GVHD prophylaxis. Graft source included pe-
ripheral blood stem cells (96) or G-CSF stimulated bonemarrow (9).
Patients were classified as high risk at HSCT (62.8%) if they had ac-
tive infection, previous immunosuppressive therapy, . 20 transfu-
sions or previous major bleed.
One hundred patients engrafted (95.2%) at a median time to neu-
trophil engraftment of 13 days (range: 8 – 19) and platelet engraft-
ment of 11 days (range: 7 – 28). The incidence of grade II-IV
acute GVHD was 24% with grade IV GVHD in 6% with chronic
GVHD in 42% of evaluable patients. Ten patients (9.5%) developed
veno-occlusive disease (VOD) of the liver while 5 (4.7%) developed
hemorrhagic cystitis; all respondedwell to supportive therapy. Over-
all incidence of graft failure was 3.8%. The 2 year overall survival is
79.1% with a survival of 97.4% in the low risk group and 68.1% in
the high risk group. This data was superior to a graft failure inci-
dence of 23% and an overall survival of 46.5% in 26 patients who un-
derwent HSCT using Cyclophosphamide based conditioning
protocols. The use of fludarabine and cyclophosphamide as condi-
tioning regimen is associated with very good outcomes in patientswith SAA. These improved results warrant randomized trials with
cyclophosphamide based conditioning regimens.26
THE NOVEL 5-GROUP CYTOGENETIC RISK CLASSIFICATION OF MYELO-
DYSPLASTIC SYNDROME (MDS), MONOSOMAL KARYOTYPE, AND OUT-
COME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
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Background:The clonal karyotype is a major risk factor for the suc-
cess of HCT in patients with MDS. Here we tested the relevance of
the new 5-group cytogenetic risk classification and monosomal kar-
yotype (MK) for relapse and survival.
Methods: Results in 1042 patients with MDS (including progres-
sion to AML), 1-75 (median 45) years old, conditioned with
various regimens and transplanted with marrow (52%) or PBPC
(48%) from related (54%) or unrelated (46%) donors were analyzed.
The association of cytogenetics with HCT outcome was examined.
Results: The 3-year probabilities of relapse for the 5-group cate-
gories very good, good, intermediate, poor, and very poor were 8%,
17%, 19%, 26%, and 48%, and overall survival was 46%, 46%,
41%, 37%, and 8%, respectively (see Table for hazard ratios [HR]).
Table.
Proportion Hazard RatioVariable Category MK (%) (HR) /CI P 5MortalityVery good 0/12 (0) 1.06/0.50-2.24 0.89Good 0/455 (0) 1 –Intermediate 2/181 (1) 1.22/0.97-1.52 0.08Poor 33/159 (21) 1.35/1.07-1.69 0.01Very poor 84/108 (78) 3.13/2.47-3.96 <0.0001RelapseVery good 0.49/0.07-3.56 0.48Good 1 –Intermediate 1.38/0.94-2.05 0.10Poor 1.83/1.25-2.68 0.002Very poor 7.46/5.20-10.69 <0.0001The impact of good and intermediate risk (5-group) on mortality
and relapse coincided with IPSS cytogenetic risks ‘‘good’’ (98%)
and ‘‘intermediate’’ (83%) respectively. IPSS ‘‘poor’’ split into
intermediate (13%), poor (50%) and very poor (36%) in the 5-group
classification. Within IPSS ‘‘poor’’, the 5-group category very poor
had worse outcome than the intermediate category (mortality
HR 5 2.82 [1.78-4.46, p\.0001]; relapse HR 5 3.57 [1.85-6.88,
p 5 .0002]). HR for relapse with MK (vs. non-MK) was 5.19
(3.80-7.09; p\0.0001) and for mortality 2.32 (1.88-
2.87;p\0.0001). MK versus non-MK in 5-group poor risk yielded
HRs of 1.62 (1.03-2.54; p 5 0.04) for mortality and 1.68
(0.80-7.53; p 5 0.17) for relapse. Corresponding figures for very
poor risk were 1.17 (0.72-1.90; p 5 0.53) and 2.0 (0.94-4.27; p 5
0.07). Dependent upon cytogenetic risk the 3-year relapse probabil-
ities were 9%-47%, and survival probabilities 81%-15%.
Adjusting for cytogenetics, older age showed a higher rate of mor-
tality (p\.0001), but not relapse (p5 0.87). The risk of mortality de-
creased over the study duration (p\0.0001); it was higher with
unrelated donors than with HLA matched-siblings (HR 5 1.34, p
5 .005), while relapse risk was lower (HR 5 0.74, p 5 .08).
Summary/Conclusions: The new 5-group cytogenetic classifica-
tion improved the 3-group IPSS model (p\0.0001 for survival and
relapse). MK information further refined the risk groups. Overall
HCT outcomes in MDS have improved, but novel approaches are
needed for patients with high risk cytogenetics.
